Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan;18(1):32-33.
doi: 10.1513/AnnalsATS.202007-881ED.

The PROSPECT Is Bright for CFTR Modulators

Kristina Montemayor  1 , Noah Lechtzin  1
Affiliations
Editorial

The PROSPECT Is Bright for CFTR Modulators

Kristina Montemayor et al. Ann Am Thorac Soc. 2021 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–689. - PubMed
    1. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science. 1992;256:774–779. - PubMed
    1. Cystic Fibrosis Foundation. Bethesda, MD: Cystic Fibrosis Foundation; 2017. Cystic Fibrosis Foundation patient registry 2017 annual data report.
    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672. - PMC - PubMed
    1. Sagel SD, Khan U, Heltshe SL, Clancy JP, Borowitz D, Gelfond D, et al. PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network Clinical effectiveness of lumacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR Ann Am Thorac Soc 20211875–83. - PMC - PubMed